FOLH1 and prostate cancer: Clinically, it was shown in a prostate cancer patient that 152Tb-PSMA-617 was safe and enabled detection of all bone and lymph node metastases, as well as of regional recurrent disease initially detected with 68Ga-PSMA-11 PET/CT one month earlier.